Zobrazeno 1 - 10 of 310 pro vyhledávání: '"H, Wasan"'
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
Autor: E. Van Cutsem, I. Danielewicz, M. P. Saunders, P. Pfeiffer, G. Argilés, C. Borg, R. Glynne-Jones, C. J. A. Punt, A. J. Van de Wouw, M. Fedyanin, D. Stroyakovskiy, H. Kroening, P. Garcia-Alfonso, H. Wasan, A. Falcone, R. Fougeray, A. Egorov, N. Amellal, V. Moiseyenko
Publikováno v: British journal of cancer, 126(11), 1548-1554. Nature Publishing Group
Scientia
Background Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03af4faff5144bcdcf5517b7b9e24306
https://doi.org/10.1038/s41416-022-01737-2
Zobrazit plný text záznamu
4
Akademický článek
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)
Autor: R. Glynne-Jones, M.R. Hall, A. Lopes, S. Pearce, V. Goh, S. Bosompem, J. Bridgewater, I. Chau, H. Wasan, B. Moran, L. Melcher, N.P. West, P. Quirke, W.-L. Wong, S. Beare, N. Hava, M. Duggan, M. Harrison
Publikováno v: Heliyon, Vol 4, Iss 9, Pp e00804- (2018)
Background: Chemoradiation (CRT) or short-course radiotherapy (SCRT) are standard treatments for locally advanced rectal cancer (LARC). We evaluated the efficacy/safety of two neoadjuvant chemotherapy (NACT) regimens as an alternative prior to total
Externí odkaz: https://doaj.org/article/b4188d0b0c0a40a689dd42b8eee8b655
Zobrazit plný text záznamu
6
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
Autor: J. Tabernero, L. Velez, T.L. Trevino, A. Grothey, R. Yaeger, E. Van Cutsem, H. Wasan, J. Desai, F. Ciardiello, T. Yoshino, A. Gollerkeri, K. Maharry, J. Christy-Bittel, S. Kopetz
Publikováno v: Scientia
ESMO Open
Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f55f353f7d3d33539bbcc2d27211073
https://lirias.kuleuven.be/handle/20.500.12942/690598
Zobrazit plný text záznamu
9
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
Autor: E, Van Cutsem, I, Danielewicz, M P, Saunders, P, Pfeiffer, G, Argilés, C, Borg, R, Glynne-Jones, C J A, Punt, A J, Van de Wouw, M, Fedyanin, D, Stroyakovskiy, H, Kroening, P, Garcia-Alfonso, H, Wasan, A, Falcone, R, Fougeray, A, Egorov, N, Amellal, V, Moiseyenko
Publikováno v: British journal of cancer. 126(11)
Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::63310fc54ca846256359e1c9d02978f3
https://pubmed.ncbi.nlm.nih.gov/35440667
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje